• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

F3基因中的人类错义变异会损害血液凝固的启动。

Human missense variants in F3 impair the initiation of blood coagulation.

作者信息

Ansari Shabbir A, Brake Marisa A, Pathak Nishtha, Flaumenhaft James T, Ludington Jacob G, Panwar Natasha, Turro Ernest, Schulman Sol

机构信息

Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.

出版信息

Blood. 2026 Feb 5;147(6):689-701. doi: 10.1182/blood.2025029571.

DOI:10.1182/blood.2025029571
PMID:41100734
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12773718/
Abstract

Tissue factor (TF), encoded by F3, binds factor VII (FVII)/activated factor VII (FVIIa) to initiate blood coagulation. Because standard clinical assays do not measure endogenous TF directly, the extent to which human F3 variants affect blood coagulation is unknown. We sought to determine the effect of the human TF missense variants with the highest allele frequency as well as additional rare variants occurring at sites predicted to perturb the initiation of blood coagulation. The variants with the highest allele frequency did not affect coagulation activation. By contrast, some rare human TF missense substitutions did profoundly affect TF-initiated plasma clotting time and the activation of FIX and FX by 2 distinct mechanisms: by precluding TF interaction with FVIIa, or by altering the TF exosite to prevent macromolecular but not amidolytic substrate cleavage. Individuals heterozygous for the rare p.Gly196Arg variant have reduced basal FVIIa-antithrombin complex and D-dimer levels but no major differences in TF or FVII levels. Gly196Arg supported impaired FVII autoactivation in vitro. These data demonstrate that rare missense variants in F3 can impair the activation of FVII, FIX, and FX, and suggest these variants impair the basal activation of blood coagulation in humans.

摘要

由F3编码的组织因子(TF)与因子VII(FVII)/活化因子VII(FVIIa)结合以启动血液凝固。由于标准临床检测方法不能直接测量内源性TF,人类F3变体对血液凝固的影响程度尚不清楚。我们试图确定具有最高等位基因频率的人类TF错义变体以及在预测会干扰凝血起始的位点出现的其他罕见变体的影响。具有最高等位基因频率的变体不影响凝血激活。相比之下,一些罕见的人类TF错义替换确实通过两种不同机制深刻影响了TF启动的血浆凝血时间以及FIX和FX的激活:通过阻止TF与FVIIa相互作用,或通过改变TF外位点以防止大分子而非酰胺分解底物的裂解。罕见的p.Gly196Arg变体杂合个体的基础FVIIa-抗凝血酶复合物和D-二聚体水平降低,但TF或FVII水平无重大差异。Gly196Arg在体外支持受损的FVII自激活。这些数据表明,F3中的罕见错义变体可损害FVII、FIX和FX的激活,并提示这些变体损害人类血液凝固的基础激活。

相似文献

1
Human missense variants in F3 impair the initiation of blood coagulation.F3基因中的人类错义变异会损害血液凝固的启动。
Blood. 2026 Feb 5;147(6):689-701. doi: 10.1182/blood.2025029571.
2
A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates.140s环中常见的人类凝血因子VII突变(A294V,c152)影响与激活剂、组织因子和底物的相互作用。
Biochem J. 2002 Apr 15;363(Pt 2):411-6. doi: 10.1042/0264-6021:3630411.
3
A thrombophilic allele of clotting Factor VII/VIIa promoting recurrent pulmonary emboli, clinical details, and a structural model of the altered protein: a case report.一个促发复发性肺栓塞的凝血因子 VII/VIIa 的血栓形成倾向等位基因:病例报告中的临床细节和改变蛋白的结构模型。
J Med Case Rep. 2023 Apr 13;17(1):161. doi: 10.1186/s13256-023-03833-0.
4
Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q).凝血因子VII与组织因子相互作用的表面等离子体共振研究。变异型FVII分子(FVII-R79Q)中组织因子结合缺陷的证明。
Biochemistry. 1994 Nov 29;33(47):14162-9. doi: 10.1021/bi00251a027.
5
The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor.凝血因子IX和凝血因子X中的N端表皮生长因子样结构域是与组织因子结合的重要识别基序。
J Biol Chem. 2002 Feb 1;277(5):3622-31. doi: 10.1074/jbc.M111202200. Epub 2001 Nov 26.
6
Tissue factor pathway.组织因子途径。
Baillieres Clin Haematol. 1994 Sep;7(3):469-84. doi: 10.1016/s0950-3536(05)80094-0.
7
Substitution of the Gla domain in factor X with that of protein C impairs its interaction with factor VIIa/tissue factor: lack of comparable effect by similar substitution in factor IX.将因子X中的γ-羧基谷氨酸(Gla)结构域替换为蛋白C的Gla结构域会损害其与因子VIIa/组织因子的相互作用:因子IX中类似替换缺乏可比效应。
J Biol Chem. 2007 May 25;282(21):15632-44. doi: 10.1074/jbc.M701908200. Epub 2007 Mar 26.
8
The endothelial protein C receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors.内皮蛋白 C 受体通过蛋白酶激活受体支持组织因子三元凝血起始复合物信号转导。
J Biol Chem. 2011 Feb 18;286(7):5756-67. doi: 10.1074/jbc.M110.201228. Epub 2010 Dec 13.
9
Engineering of substrate selectivity for tissue factor.factor VIIa complex signaling through protease-activated receptor 2.通过蛋白酶激活受体 2 工程化组织因子.因子 VIIa 复合物信号传导的底物选择性。
J Biol Chem. 2010 Jun 25;285(26):19959-66. doi: 10.1074/jbc.M110.101030. Epub 2010 Apr 13.
10
Tissue factor pathway.组织因子途径。
Baillieres Best Pract Res Clin Haematol. 1999 Sep;12(3):361-72. doi: 10.1053/beha.1999.0030.

本文引用的文献

1
Cryo-EM structure of the tissue factor/factor VIIa complex with a factor X mimetic reveals a novel allosteric mechanism.组织因子/因子VIIa复合物与X因子模拟物的冷冻电镜结构揭示了一种新型变构机制。
Blood. 2025 Aug 14. doi: 10.1182/blood.2025029430.
2
Membrane-bound model of the ternary complex between factor VIIa/tissue factor and factor X.因子VIIa/组织因子与因子X之间三元复合物的膜结合模型
Blood Adv. 2025 Feb 25;9(4):729-740. doi: 10.1182/bloodadvances.2024014845.
3
Regulation of tissue factor activity by interaction with the first PDZ domain of MAGI1.
通过与MAGI1的第一个PDZ结构域相互作用对组织因子活性的调节
Thromb J. 2024 Jan 17;22(1):12. doi: 10.1186/s12959-023-00580-6.
4
Human Genetic Variation in F3 and Its Impact on Tissue Factor-Dependent Disease.人类 F3 基因变异及其对组织因子依赖性疾病的影响。
Semin Thromb Hemost. 2024 Mar;50(2):188-199. doi: 10.1055/s-0043-1769079. Epub 2023 May 18.
5
Genetic duplication of tissue factor reveals subfunctionalization in venous and arterial hemostasis.组织因子基因复制揭示了静脉和动脉止血中的次功能化。
PLoS Genet. 2022 Nov 30;18(11):e1010534. doi: 10.1371/journal.pgen.1010534. eCollection 2022 Nov.
6
Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis.凝血因子 VII 的生化、分子和临床方面及其在止血和血栓形成中的作用。
Haematologica. 2021 Feb 1;106(2):351-362. doi: 10.3324/haematol.2020.248542.
7
How the tissue factor-VIIa complex keeps two substrates in the loop.组织因子 - VIIa 复合物如何使两种底物保持在循环中。
J Thromb Haemost. 2021 Jan;19(1):52-54. doi: 10.1111/jth.15148.
8
Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals.对 30931 个人的 90 种心血管蛋白进行基因组和药物靶点评估。
Nat Metab. 2020 Oct;2(10):1135-1148. doi: 10.1038/s42255-020-00287-2. Epub 2020 Oct 16.
9
A serine loop in tissue factor mediates substrate selectivity by the tissue factor-factor VIIa complex.组织因子中的丝氨酸环通过组织因子-因子 VIIa 复合物来介导底物选择性。
J Thromb Haemost. 2021 Jan;19(1):75-84. doi: 10.1111/jth.15087. Epub 2020 Oct 1.
10
A coagulation defect arising from heterozygous premature termination of tissue factor.由组织因子杂合性提前终止引起的凝血缺陷。
J Clin Invest. 2020 Oct 1;130(10):5302-5312. doi: 10.1172/JCI133780.